Hepatocellular carcinoma
Not recruitingStudy on the Safety and Effectiveness of 166Holmium Radiation Therapy with Atezolizumab and Bevacizumab for Patients with Non-Resectable Liver Cancer
Study on the Safety and Effectiveness of 166Holmium Radiation Therapy with Atezolizumab and Bevacizumab for Patients with Non-Resectable Liver Cancer
- Disease:Hepatocellular carcinoma
- Substances:AtezolizumabBevacizumab+1
France- Participants:18–64 years · 65+ years
- Substances:Atezolizumab
- Sponsor:Institut Gustave Roussy









